MAPT and tauopathy: The results presented here clearly confirms that off-target binding of Tau tracers may hamper detection of Tauopathy, and although second generation of Tau tracers have shown negligible monoamine oxidase binding 88, 89, binding to other molecules such as neuromelanin and melanin still present a challenge to development of a Tau-specific PET tracer 87, 90, 91.